文献速递姑息放疗与转移瘤放疗物理与技术

BMETS:骨转移生存估计的改进统计方法

Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-05-22

本研究针对症状性骨转移患者开发了BMETS机器学习模型,基于27个预后变量预测生存,并与两种简化Cox模型比较。结果显示BMETS在3、6、12个月的tAUC均优于简化模型,时间验证集表现相似,并开发了网络平台辅助临床使用。

要点

  • BMETS基于27个临床变量,使用随机生存森林预测症状性骨转移患者生存。
  • BMETS在3、6、12个月的tAUC分别为0.83、0.81、0.81,优于C-3和W-2模型。
  • 时间验证集中BMETS的tAUC分别为0.86、0.82、0.78,模型性能保持稳定。

核心结论

  • 对于症状性骨转移患者,BMETS相比更简单的传统模型提高了生存预测准确性。
  • 模型性能在时间验证集中得到保持。
  • 为便于临床使用,开发了用于数据录入和展示BMETS预测生存概率的网络平台。

研究设计与样本

  • 研究纳入2007年1月至2013年1月期间因症状性骨转移接受姑息放疗评估的397例患者共492个骨位点。
  • 收集27个临床变量,使用随机生存森林构建BMETS模型,主要结局为从咨询到死亡的时间。
  • 采用交叉验证评估模型性能,以时间依赖AUC(tAUC)衡量,并与Chow三变量模型(C-3)和Westhoff两变量模型(W-2)比较。
  • 时间验证使用2018年85例患者共104个骨位点的独立数据集评估BMETS的tAUC。

主要发现

  • 中位生存期为6.4个月。
  • 变量重要性最高的是体能状态、血细胞计数、近期系统治疗类型和同期非骨姑息放疗。
  • BMETS在3、6、12个月的tAUC分别为0.83、0.81、0.81。
  • C-3模型在3、6、12个月的tAUC分别为0.78、0.76、0.74;W-2模型分别为0.80、0.78、0.77。
  • 时间验证集中BMETS的tAUC分别为0.86、0.82、0.78。

关键数值与推荐

  • BMETS在3、6、12个月的tAUC分别为0.83、0.81、0.81,显示优秀区分度。
  • C-3模型在3、6、12个月的tAUC分别为0.78、0.76、0.74。
  • W-2模型在3、6、12个月的tAUC分别为0.80、0.78、0.77。
  • 时间验证集中BMETS的tAUC分别为0.86、0.82、0.78。

临床怎么用

  • BMETS可用于症状性骨转移患者放疗前的生存预测,辅助临床决策。
  • 已开发网络平台便于数据录入和展示BMETS预测的生存概率。

局限性

  • 研究为单中心回顾性数据,样本量有限。
  • 时间验证集样本量较小(85例患者,104个骨位点)。
  • 未报告外部多中心验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether a machine learning approach optimizes survival estimation for patients with symptomatic bone metastases (SBM), we developed the Bone Metastases Ensemble Trees for Survival (BMETS) to predict survival using 27 prognostic covariates. To establish its relative clinical utility, we compared BMETS with 2 simpler Cox regression models used in this setting. METHODS AND MATERIALS: For 492 bone sites in 397 patients evaluated for palliative radiation therapy (RT) for SBM from January 2007 to January 2013, data for 27 clinical variables were collected. These covariates and the primary outcome of time from consultation to death were used to build BMETS using random survival forests. We then performed Cox regressions as per 2 validated models: Chow's 3-item (C-3) and Westhoff's 2-item (W-2) tools. Model performance was assessed using cross-validation procedures and measured by time-dependent area under the curve (tAUC) for all 3 models. For temporal validation, a separate data set comprised of 104 bone sites treated in 85 patients in 2018 was used to estimate tAUC from BMETS. RESULTS: Median survival was 6.4 months. Variable importance was greatest for performance status, blood cell counts, recent systemic therapy type, and receipt of concurrent nonbone palliative RT. tAUC at 3, 6, and 12 months was 0.83, 0.81, and 0.81, respectively, suggesting excellent discrimination of BMETS across postconsultation time points. BMETS outperformed simpler models at each time, with respective tAUC at each time of 0.78, 0.76, and 0.74 for the C-3 model and 0.80, 0.78, and 0.77 for the W-2 model. For the temporal validation set, respective tAUC was similarly high at 0.86, 0.82, and 0.78. CONCLUSIONS: For patients with SBM, BMETS improved survival predictions versus simpler traditional models. Model performance was maintained when applied to a temporal validation set. To facilitate clinical use, we developed a web platform for data entry and display of BMETS-predicted survival probabilities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Alcorn SR, Fiksel J, Wright JL, et al. Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model. Int J Radiat Oncol Biol Phys. 2020. PMID: 32446952. doi:10.1016/j.ijrobp.2020.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。